A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Clinical trial NCT05890742 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05890742
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-25
- Primary completion
- 2028-04-15
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.